Considering that a specific therapy is still missing in LGLL and that current immunosuppressive drugs do not provide satisfying responses, the above-mentioned clinical impact of STAT signaling in LGLL makes these molecules attractive new targets for drug development. The gene discussed is SOAT1; the disease is T-cell large granular lymphocyte leukemia.